These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8455369)

  • 1. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure.
    Raine AE; Bedford L; Simpson AW; Ashley CC; Brown R; Woodhead JS; Ledingham JG
    Kidney Int; 1993 Mar; 43(3):700-5. PubMed ID: 8455369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenous calcitriol on platelet intracellular calcium in uremic hemodialysis patients with secondary hyperparathyroidism.
    Lin SH; Shieh SD; Chyr SH; Lu KC; Lin YF; Diang LK; Chou TC; Ding YA
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Oct; 54(4):240-5. PubMed ID: 7982134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperparathyroidism, glucose tolerance and platelet intracellular free calcium in chronic renal failure.
    Lu KC; Shieh SD; Lin SH; Chyr SH; Lin YF; Diang LK; Li BL; Sheu WH; Ding YA
    Q J Med; 1994 Jun; 87(6):359-65. PubMed ID: 8041868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism.
    Reichel H; Deibert B; Schmidt-Gayk H; Ritz E
    Nephrol Dial Transplant; 1991; 6(3):162-9. PubMed ID: 1866044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
    Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values.
    Brossard JH; Cloutier M; Roy L; Lepage R; Gascon-Barré M; D'Amour P
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3923-9. PubMed ID: 8923839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure.
    Cardinal H; Brossard JH; Roy L; Lepage R; Rousseau L; D'Amour P
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3839-44. PubMed ID: 9814455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis.
    González MT; Torregrosa JV; Colomé E; Mendia A; Pavesi M
    Nephron Clin Pract; 2008; 108(2):c141-7. PubMed ID: 18259100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitamin D therapy in predialysis renal failure].
    Ando R
    Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.